ILUMYA

Mumbai – October 30, 2026 -- The U.S. Food and Drug Administration has approved Sun Pharma's supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) in adults with active psoriatic arthritis (PsA), the first expansion of the IL-23 inhibitor beyond plaque psoriasis since its 2018 U.S. approval.

Approval addresses a U.S. patient pool of about 2.4 million

Approximately 2.4 million Americans live with PsA, according to Sun Pharma. The company states that roughly 1 in 3 people with psoriasis also have PsA, and that more than 15% of psoriasis patients may have undiagnosed PsA.

ILUMYA was previously cleared only for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.